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Abstract: Modification of the Lipid A phosphates by posi-
tively charged appendages is a part of the survival strategy
of numerous opportunistic Gram-negative bacteria. The
phosphate groups of the cystic fibrosis adapted Burkholderia
Lipid A are abundantly esterified by 4-amino-4-deoxy-b-l-
arabinose (b-l-Ara4N), which imposes resistance to antibiotic
treatment and contributes to bacterial virulence. To establish
structural features accounting for the unique pro-inflamma-
tory activity of Burkholderia LPS we have synthesised Lipid A
substituted by b-l-Ara4N at the anomeric phosphate and its
Ara4N-free counterpart. The double glycosyl phosphodiester
was assembled by triazolyl-tris-(pyrrolidinyl)phosphonium-as-
sisted coupling of the b-l-Ara4N H-phosphonate to a-lactol
of b(1!6) diglucosamine, pentaacylated with (R)-(3)-acyloxy-
acyl- and Alloc-protected (R)-(3)-hydroxyacyl residues. The in-
termediate 1,1’-glycosyl-H-phosphonate diester was oxidised
in anhydrous conditions to provide, after total deprotection,
b-l-Ara4N-substituted Burkholderia Lipid A. The b-l-Ara4N
modification significantly enhanced the pro-inflammatory
innate immune signaling of otherwise non-endotoxic Bur-
kholderia Lipid A.
Introduction
The B. cepacia complex (BCC) is a group of opportunistic bac-
terial species that can cause severe lung infections and over-
whelming septicaemia in patients with cystic fibrosis (CF) re-
sulting in extremely high mortality (the “cepacia syndrome”).[1]
Lipopolysaccharide (LPS) belongs to the major virulence factors
of BCC species.[2] The pro-inflammatory activity of lipooligosac-
charides (LOS) from BCC isolates has been extensively studied.
Heterogeneous tetra- and pentaacylated LOS/Lipid A isolates
from B. mallei,[3] B. multivorans,[4] B. cenocepacia,[5, 6] B. cepacia[2]
and B. dolosa[7] were reported to be very potent activators of
human (h) LPS-sensing innate immune receptor, Toll-like Re-
ceptor 4 (TLR4)–myeloid differentiation-2 (MD-2) complex. Fur-
thermore, it has been previously established that the terminal
membrane-bound portion of LPS, glycophospholipid Lipid A, is
primarily responsible for induction of pro-inflammatory signal-
ling, which was shown both with isolated[8] and synthetic
Lipid A derivatives.[9, 10] The structural basis of the LPS-triggered
activation of innate immune response was revealed in the
seminal work deciphering the co-crystal structure of E.coli Re-
LPS with human MD-2·TLR4 complex.[11]
Lipid A possesses a rather conserved structure that is charac-
terized by a b(1!6)-linked diglucosamine backbone substitut-
ed by the long chain (R)-3-acyloxyacyl- and/or (R)-3-hydroxyac-
yl residues at positions 2, 3, 2’ and 3’ and the phosphate
groups attached at positions 1 and 4’.[12] In some LPS the
Lipid A phosphates are further substituted by compounds that
reduce its net negative charge, such as ethanolamine,[13,14] 4-
amino-4-deoxy-b-l-arabinose (b-l-Ara4N)[2,15] or galactosamine
in Francisella[13] and glucosamine in Bordetella species.[16] These
covalent modifications confer resistance to the endogenous
cationic antimicrobial peptides (CAMPs) and aminoglycosides
and are associated with increased bacterial virulence.[17, 18]
Unlike E. coli Lipid A, which encounters a substitution by b-l-
Ara4N only under particular laboratory stress conditions,[19] Bur-
kholderia species express a very intricate b-l-Ara4N-modified
Lipid A when isolated from the specimens of CF patients
(Figure 1).[2] Progressive antibiotic treatment imposes selective
pressure on BCC in the airways of immunocompromised pa-
tients, leading to substitution of the Lipid A phosphates with
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Ara4N, which results in reduction of ionic attraction and, as
a consequence, in an amplified resistance to CAMPs and ami-
noglycosides.[1] Thus, covalent modification of the Lipid A
phosphates with Ara4N, which is associated with chronic in-
flammation and decreased survival, is considered as a crucial
attribute for the virulence of the CF adapted BCC species.[2]
Interestingly, b-l-Ara4N-1-phosphate residues were found to
be characteristic also for pentaacylated Lipid A structures of an
opportunistic pathogen Serratia marcescens[20] as well as of B.
thailandensis and B. pseudomallei, a causative agent of melioi-
dosis (responsible for chronic abscesses and acute septicae-
mia),[21] contributing to pathogenesis and endotoxicity. Similar-
ly, P. aeruginosa Lipid A isolated from the airways of CF patients
entails a unique Ara4N modification exclusively at the 1-phos-
phate, promoting acute inflammation of the airways.[22]
Although it is generally believed that only hexaacylated
Lipid A patterns (such as from E. coli) are capable of eliciting
a robust TLR4-mediated innate immune response,[23,24] undera-
cylated Ara4N-modified Burkholderia Lipid A/LOS isolates effi-
ciently induce the innate immune signalling, which is compara-
ble to that produced by hexaacylated E. coli LPS.[5] A high
degree of heterogeneity of LOS/Lipid A obtained from bacterial
isolates with regard to the lipid chain content and the degree
of Ara4N substitution at the Lipid A phosphates, which is usu-
ally given like “non-stoichiometric”, makes it difficult to assess
which structural features of Burkholderia Lipid A, such as acyla-
tion pattern, the length of (R)-3-hydroxyacyl chains (C16–
C14)
[25,26] (compared with C12–C14 in E. coli LPS) or modification
of the phosphates with Ara4N, are responsible for the atypical
pro-inflammatory activity. Of particular interest are the Lipid A
structures corresponding to highly pro-inflammatory B. cenoce-
pacia[5] and B. caryophilli[27] LPS, which are esterified by Ara4N
exclusively at the anomerically-linked 1-phosphate. Since the
1-phosphate of E. coli Lipid A is directly involved in the homo-
dimerization of MD-2·TLR4-LPS complexes, which results in the
downstream inflammatory signalling,[11] the appendage of
Ara4N possessing a positively charged amino group could en-
hance ionic attraction at the dimerization interface, thereby
tightening the ligand–protein binding.
To establish the structural aspects accounting for the unique
immuno-stimulating potential of Burkholderia Lipid A and to
clarify the functional outcome of the Ara4N modification, the
chemical synthesis of homogeneous structurally defined
Lipid A corresponding to native Burkholderia LPS is required.
The availability of purely synthetic Ara4N-modified Burkholderia
Lipid A would also provide a reliable tool for extensive biosyn-
thetic studies. Herein, we report on the total synthesis of pen-
taacyl Burkholderia Lipid A esterified by b-l-Ara4N at the
anomeric phosphate 1 and its Ara4N-free counterpart 2 and
the biological activity of synthetic compounds at human
TLR4·MD-2 complex.
Results and Discussion
The major challenge in the chemical synthesis of Lipid A sub-
stituted by glycosidically linked b-l-Ara4N at 1-phosphate re-
sides in the assembly of an intrinsically labile double glycosyl
phosphodiester under simultaneous stereocontrol at two gly-
cosidic centres. We have previously established that the H-
phosphonate approach is more advantageous for this purpose
compared with the phosphoramidite methodology in regard
to higher stereoselectivity and sufficient stability of the inter-
mediate phosphite derivatives (H-phosphonates).[28] Therefore,
in our synthetic approach we relied on the initial preparation
of the anomerically pure H-phosphonate of 4-azido-protected
b-l-Ara4N (C), which would then be coupled to the pentaacy-
lated b(1!6) diglucosamine lactol (B) (Scheme 1). Because of
the presence of a masked amino group in the key trisaccharide
phosphodiester (A) the application of benzyl protecting
groups, which could be cleaved either by hydrogenolysis on
[Pd(OH)2] in acidic conditions
[29,30] (incompatible with the pres-
ence of an acid-labile double glycosyl phosphodiester linkage),
or by reduction in Birch conditions (Na/NH3),
[31] which would
lead to the loss of b-acyloxyacyl chains, was avoided. Further-
more, benzyl protections of b-hydroxyl groups in fatty acids
were reported to be highly susceptible to air oxidation and
easily transformed to benzoyl groups.[32] Allyloxycarbonyl
(Alloc) protection, which is decently stable and can be re-
moved under mild neutral conditions was chosen as perma-
nent protecting group both for the Lipid A backbone and for
(R)-3-hydroxy-fatty acids[33] (Scheme 1). To minimize the
number of deprotection steps, an allyl-protected phosphorami-
dite[34] F was used both for the phosphorylation of the diol E
at O-4’ and O-1 to furnish bisphosphate D and for the phos-
phate instalment at position 4’ in the route to compound 1. A
common orthogonally protected, pentaacylated (by long-chain
(R)-3-(allyloxycarbonyl)oxyacyl- and (R)-3-acyloxyacyl residues)
disaccharide G served as precursor for both target Lipid A
1 and 2. High amphiphilicity of the intermediates A, B and E
and a combination of peculiar physico-chemical properties in
the target amphiphilic zwitterionic Lipid A 1 possessing inher-
ently labile 1,1’-glycosyl phosphodiester linkage imposed addi-
Figure 1. Major Burkholderia Lipid A 1 substituted by b-l-Ara4N at the anom-
erically linked phosphate and unmodified Burkholderia Lipid A 2.
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tional challenges with respect to the synthesis and final purifi-
cation.
Synthesis of b-l-Ara4N H-phosphonate
First, we focused on the stereoselective preparation of the H-
phosphonate of b-l-Ara4N. Generally, glycosyl phosphites (H-
phosphonates) can be easily obtained from the corresponding
hemiacetals by reaction with the activated PIII reagents, such
as salicylchlorophosphite.[35,36] It has been previously shown
that the anomeric ratio of glycosidic H-phosphonates obtained
by reaction with the activated phosphites commonly reflects
the configuration of the starting lactol.[37–39] In-situ anomerisa-
tion attempts of the 4-azido-
protected l-Ara4N lactols pro-
vided variable b/a ratios,[40]
therefore, we had to rely on
a careful attenuation of the pro-
tecting group pattern at posi-
tions 2 and 3, which would
allow fast and uncomplicated
isolation of the anomerically
pure b-l-Ara4N H-phosphonate.
Luckily, among a series of 2,3-di-
O-protecting groups tested, the
Alloc group, which was also ap-
plied as a permanent protection
for the diglucosamine back-
bone, provided a very satisfacto-
ry outcome.
The anomeric allyl group of
the known diol 3[41] was first
isomerised into a propenyl
group by the action of
[IrI(MePPh2)2(cod)]PF6 (cod=1,5-
cyclooctadiene) catalyst to give
1-O-propenyl glycoside 4 in
quantitative yield (Scheme 2).
The latter was treated with ally-
loxycarbonyl chloride in the
presence of N,N,N’,N’-tetrame-
thylethylenediamine (TMEDA)[42]
to furnish 4a, which was depro-
tected at the anomeric position
by aqueous iodine-promoted hydrolysis[43] to provide anomeric
lactol 5 (b/a=2:1) in 75% yield. Lactol 5 was subsequently
treated with 2-chloro-1,3,2-benzodioxaphosphorin-4-one (salic-
yl chlorophosphite, SalPCl) in the presence of pyridine to fur-
nish an anomeric mixture (b/a=2:1) of the H-phosphonates.
The axial H-phosphonate 6 was readily isolated by a single
chromatography on silica gel as ammonium salt in 55% yield
(Scheme 2).
Synthesis of the common orthogonally protected pentaacy-
lated bGlcN(1!6)aGlcN intermediate
The synthesis of the pentaacylated b(1!6) diglucosamine
backbone commenced with the preparation of the GlcN-based
donor and acceptor molecules (Scheme 3). To this end, the p-
methoxybenzylidene acetal 8 was acylated by (R)-3-(allyloxycar-
bonyloxy)tetradecanoic acid 9 in the presence of strictly equi-
molar amount of diisopropylcarbodiimide (DIC) and catalytic
amount of 4-N,N-dimethylaminopyridine (DMAP) at 0 8C (to
avoid a formation of a,b-elimination product at fatty acid),[44]
which afforded 12 in nearly quantitative yield. Reductive open-
ing of 4,6-p-methoxybenzylidene acetal with sodium cyanobor-
ohydride and trimethylsilyl chloride in acetonitrile furnished
a mixture of two isomeric products, 6-OH derivative 13 and its
4-OH regio-isomer 14. To avoid tedious separation of the co-
migrating products, the mixture was subjected to regioselec-
Scheme 2. Synthesis of b-l-Ara4N H-phosphonate. a) [IrI(MePPh2)2(cod)]PF6,
H2, THF, 99%; b) AllocCl, TMEDA, CH2Cl2 ; c) I2, H2O, 0 8C, 75% for two steps;
d) SalPCl, Py, THF, then Et3N, H2O, 55%.
Scheme 1. Retrosynthetic analysis of Burkholderia Lipid A 1 and 2.
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tive 6-O-protection with allyloxycarbonyl group by the action
of AllocCl in the presence of a mild base sym-collidine, which
transformed compound 13 into 6-O-Alloc-protected 15, where-
as the 4-OH derivative 14 was unaffected. The resulting mix-
ture (14+15) was separated by chromatography to provide
15 in 92% yield and quantitatively recovered 14. Orthogonally
protected 15 was desilylated at the anomeric position by treat-
ment with triethylamine tris(hydrogenfluoride) (TREAT-HF) buf-
fered by addition of Et3N (until pH 6.5) to keep the acid-labile
6-O-p-methoxybenzyl (PMB) group unaffected. The resulting
lactol 16 was transformed into trichloroacetimidate (TCA)
donor 17. The secondary hydroxyl group at C-4 in 14 was
treated with AllocCl in the presence of TMEDA to afford fully
protected monosaccharide 18. The trichloroethoxycarbonyl
(Troc) group in 18 was reductively cleaved by treatment with
Zn in acetic acid/dioxane and the resulting amine was acylated
by DIC-activated 3-O-Alloc-protected fatty acid 10 to provide
19. The acceptor 20 was obtained by acidic hydrolysis of the
PMB group in 19 with trifluoroacetic acid (TFA) at 0 8C.
Trifluoromethanesulfonic acid (TMSOTf)-promoted glycosyla-
tion of 20 by TCA donor 17 at 65 8C furnished b(1!6) disac-
charide 21 in 90% yield (Scheme 4). Reduction of the 2’N-Troc
group by Zn/AcOH in dioxane followed by N-acylation with
(R)-3-acyloxyacyl fatty acid 11 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl)
resulted in orthogonally protected common intermediate 22.
Synthesis of Ara4N-modified Lipid A 1 and its non-modified
counterpart 2
To differentiate between the PMB group at C-4’ and TBDMS
group at C-1 in 22, a single deprotection step consisting of
a treatment with TFA in CH2Cl2 was applied, which resulted in
the fast hydrolysis of 4’-O-PMB group and partial acid-catalysed
deprotection of the anomeric TBDMS group, to afford, after
separation by chromatography on silica gel, the 4’-OH deriva-
tive 23 (75%) and a-lactol 24 (a/b=10:1) having a free OH
group at C-4’ (7%) (Scheme 4). Compound 24 was phosphory-
lated by reaction with diallyl(N,N-diisopropyl)phosphoramidite
in the presence of a mild acid catalyst 1H-tetrazole and succes-
sive oxidation of the intermediate phosphites with 2-(phenyl-
sulfonyl)-3-(3-nitrophenyl)oxaziridine (PNO)[45,46] to provide
anomerically pure 4’,1-bisphosphotriester 25. A small propor-
tion of the thermodynamically less stable b-GlcN 1-phosphate
derivative, which was apparently formed in a phosphitylation
reaction of the 10:1 mixture of the anomeric lactols 24, had
obviously hydrolysed upon purification on silica gel.[47] 4’-Hy-
droxy compound 23 was similarly phosphorylated at O-4’,
which resulted in a protected monophosphate 26 in 93%
yield. The TBDMS group at C-1 was cleaved by reaction with
TREAT-HF to give anomeric lactol 27 with a high preponder-
ance of a-anomer (a/b=10:1), which was rationalized by a pos-
sible stabilization of the axial orientation of the 1-OH group by
intramolecular hydrogen bonding with the 2-NH group.[28,39]
Coupling of lactol 27 (a/b=10:1) to the anomerically pure
glycosyl H-phosphonate 6 promoted by 3-nitro-1,2,4-triazol-1-
yl-tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate
(PyNTP)[48] in the presence of 2,6-lutidine afforded intermediate
1,1’-glycosyl H-phosphonate diester 28a (Supporting Informa-
tion, Figure 1). The progression of the reaction was followed
by 31P NMR spectroscopy either by performing the H-phospho-
nate coupling in the NMR tube (CD3CN) or by NMR spectro-
scopic analysis of a small aliquot of the reaction mixture. The
reaction is supposed to proceed through formation of the re-
active tetracoordinated PIII-intermediates such as H-pyro-
phosphonates[49] and nitrotriazol-1-yl-phosphites,[50] which can
be detected by 31P NMR spectroscopy in the absence of hy-
droxylic component. Upon shortage of nucleophilic compo-
nent 27, activation of Ara4N H-phosphonate 6 resulted in
eventual formation of nitrotriazol-1-yl-H-phosphonate 6a (Sup-
porting Information, Figure 2), which was detected by 31P NMR
spectroscopy (d=13.1 and 14.1 ppm, JPH=652 and 656 Hz, re-
spectively). The formation of the intermediate double anomeric
H-phosphonate diester was confirmed by the appearance of
the characteristic PH-coupled signals corresponding to (Rp/Sp)-
diastereomeric mixture 28a (d=7.6 and 8.0 ppm, JP-H=745
Scheme 3. Synthesis of GlcN donor and acceptor molecules. a) Anisaldehyde
dimethyl acetal, CSA, CH3CN, 75%; b) 9, DIC, cat. DMAP, CH2Cl2, 0 8C, 97%;
c) NaCNBH3, TMSCl, MeCN, 90%; d) AllocCl, collidine, CH2Cl2, 45 8C, 96%;
e) TREAT-HF, NEt3, THF, 98%; f) Cl3CCN, Cs2CO3, CH2Cl2, 80%; g) AllocCl,
TMEDA, CH2Cl2, 95%, k) Zn, dioxane/AcOH, 2:1, then 10, DIC, CH2Cl2, 0 8C,
82%; l) TFA, CH2Cl2, 92%.
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and 754 Hz, respectively ; Supporting Information, Figure 3).
For the full conversion of lactol 27 into the H-phosphonate
diester 28a, application of a large excess (up to 10 equivalents,
compared with 27) of the polar, charged H-phosphonate 6
was necessary, which might be explained by the propensity of
highly hydrophobic pentaacylated lactol 27 to undergo aggre-
gation in a polar reaction solvent (acetonitrile), which could
render the 1-OH group less accessible, necessitating a higher
concentration of the activated H-phosphonate 6 for comple-
tion of the coupling. The oxidation of 28a was performed in
anhydrous conditions by first transformation of the H-phos-
phonate 28a (tetra-coordinated) into the phosphite 28b
(three-coordinated) by treatment with N,O-bis(trimethylsilyl)a-
cetamide (BSA)[51,52] in the presence of Et3N, followed by oxida-
tion with (1S)-(+)-(10-camphorsulfonyl)- oxaziridine (CSO)[53] to
furnish 1,1’-glycosyl phosphodiester 28. The anomeric configu-
ration about aGlcN(1!P !1)bAra4N linkage was confirmed by
the corresponding coupling constants JH1,H2=3.3 and JH1,P=
7.1 Hz for a-d-gluco- and JH1,H2=3.5 and JH1,P=7.4 Hz for b-l-
arabino-anomers, respectively.
Initial attempts to perform the H-phosphonate coupling be-
tween 27 and 6 under standard conditions, which were suc-
cessfully employed for the preparation of glycosyl phospho-
diesters (activation with pivaloyl chloride followed by oxidation
with aqueous I2 at reduced temperature),
[38,39, 54] did not result
in the formation of the target trisaccharide 28. This could be
explained by both a predisposition of the N-acylated GlcN de-
rivatives to formation of oxazolines in the presence of an
excess of chloroanhydrides[55] and the instability of 1,1’-glyco-
sylphosphite diester in the harsh conditions of aqueous I2-oxi-
dation.
Total cleavage of Alloc-[56] and Allyl-protecting groups[57] in
25 and 28 was smoothly performed with a catalytic amount of
[CpRuIV(p-C3H5)(2-quinolinecarboxylato)]PF6 (Cp=cyclopenta-
dienyl) complex[58] in MeOH at RT under neutral pH. This proce-
dure was perfectly compatible with the presence of a labile
Scheme 4. Synthesis of b-l-Ara4N-modified Burkholderia Lipid A. a) TMSOTf, CH2Cl2, 65 8C, MS 4 , 90%; b) Zn, dioxane/AcOH, 2:1 then 11, EDC·HCl, CHCl3,
0 8C, 67%; c) TFA, CH2Cl2, 75% for 23, 7% for 24 ; d) 1) iPr2NP(OAllyl)2, 1H-tetrazole, CH3CN; 2) PNO; 84% for 25, 93% for 26 ; e) [CpRu
IV(p-C3H5)(2-quinolinecar-
boxylato)]PF6, CHCl3/MeOH, 4:1, 50%; f) TREAT-HF, THF, 87%; g) 6, PyNTP, 2,6-lutidine, CH3CN/CH2Cl2, 4:1; h) BSA, NEt3 ; i) CSO, 61% for three steps; j) 1. PtO2,
H2, toluene/MeOH, 4:1, 2. [CpRu
IV(p-C3H5)(2-quinolinecarboxylato)]PF6, CHCl3/MeOH, 4:1, 57% for two steps.
Chem. Eur. J. 2015, 21, 4102 – 4114 www.chemeurj.org  2015 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim4106
Full Paper
double glycosyl phosphodiester linkage, which was not affect-
ed under applied conditions and no hydrolysis products were
observed (according to 1H NMR spectroscopy and HRMS of the
reaction mixture, data not shown). Finally, the azido group at
Ara4N moiety was reduced by hydrogenation on PtO2 in tolu-
ene/methanol, 4:1. The target amphiphilic Lipid A 1 and 2
were purified by using size exclusion chromatography on Se-
phadex SX1 and Sephadex LH-20 supports, which allowed for
separation from ruthenium oxide anion contaminations
(RuO4
 : yellowish, RuO4
2 : pink) and by anion-exchange chro-
matography on DEAE cellulose by elution with CHCl3-MeOH-
aqueous triethylammonium acetate (TEAA) buffer, which simul-
taneously afforded a single salt form at the phosphates (trie-
thylammonium salt).[59] The zwitterionic phosphodiester 1 was
easily hydrolysed at higher concentrations of TEAA buffer
(pH 7) giving rise to the phosphate 2 and free Ara4N, which
could be explained by the intramolecular nucleophilic attack
of the amino group at C-4’’ of Ara4N on the phosphorus atom.
Biological evaluation
The ability of synthetic Ara4N-modified Burkholderia Lipid A
1 and its non-modified counterpart 2 to initiate the pro-inflam-
matory signaling was first assessed in the hTLR4/hMD-2/CD14
transfected human embryonic kidney (HEK)293 cells (HEK-Blue)
through monitoring the activation of NF-kB signaling by meas-
uring the induction of secreted alkaline phosphatase (SEAP)
whose expression is under control of an NF-kB-responsive pro-
moter. The Ara4N-modified Lipid A 1 was considerably less effi-
cient than E. coli Re-LPS, but showed a significantly more
potent NF-kB stimulation profile reaching 80% of the activity
of E. coli Re-LPS at a concentration 100 ngmL1, compared
with the 1,4’-bisphosphate Lipid A 2, which was largely inac-
tive (Figure 2).
Next, Lipid A 1 and 2 were examined for the propensity to
initiate the expression of interleukin-8 (IL-8) in the human
monocytic macrophage cell line THP-1, which expresses cell
surface receptors MD-2, CD14 and TLR4. Although the pentaac-
yl bisphosphate Lipid A 2 revealed no activity at all, the Ara4N-
modified Lipid A 1 was efficient in induction of the expression
of IL-8, though again at significantly higher doses than E. coli
LPS (Figure 3).
Evidently, positively charged Ara4N modification at the
anomerically linked phosphate of Burkholderia Lipid A 1 plays
an important role in enhancement of the pro-inflammatory sig-
nalling of otherwise inactive long-chain pentaacylated Lipid A
2. Ara4N might actively participate in the dimerization inter-
face of two TLR4/MD-2/Lipid A complexes, perhaps, by estab-
lishing additional ionic contacts between its 4-amino group
and specific amino acid residues on the second TLR4*, which
results in the augmented activation. Furthermore, dampened
pro-inflammatory signaling induced by pentaacylated Ara4N-
Lipid A 1 compared with hexaacyl E. coli LPS/Re-LPS is presum-
ably related to its underacylated structure. High E. coli LPS-like
activity of the BCC bacterial LOS isolates could be also associ-
ated with the presence of the core-sugar region attached at
position 6’ of Lipid A,[7] leading to enhanced TLR4 activation,
which has been already shown for the underacylated LOS var-
iants of other bacterial species.[60] Moreover, glycosylation of
Lipid A by negatively charged 3-deoxy-d-manno-octulosonic
acid (Kdo) residues (as in LOS isolates) can also result in the
boosted pro-inflammatory signaling.[10,61,62]
Conclusion
The first synthesis of 4-amino-4-deoxy-b-l-arabinose-modified
Lipid A corresponding to a partial structure of pentaacylated
Burkholderia cepacia complex LPS has been achieved. The H-
phosphonate approach has been applied for the assembly of
a double glycosyl phosphodiester linkage involving the
anomeric centres of a-d-GlcN and b-l-Ara4N. Phosphonium re-
agent (PyNTP)-mediated coupling and non-aqueous oxaziridine
(CSO)-promoted oxidation of three-coordinated 1,1’-glycosyl
phosphite-triester intermediate were found superior to con-
ventional coupling conditions (PivCl, aqueous I2 oxidation). Per-
manent Alloc protecting groups both on a trisaccharide back-
bone of Lipid A 1 and on the b-hydroxyacyl chains were effi-
ciently cleaved simultaneously with allyl-protecting groups on
the phosphates by application of an RuIV complex, preserving
Figure 3. Dose-dependent expression of IL-8 induced by synthetic Burkhol-
deria Lipid A 2 and Ara4N-modified Lipid A 1 in human macrophage cell line
THP-1 compared to E. coli O111:B4 LPS.
Figure 2. Dose-dependent activation of TLR4 signalling in hTLR4/hMD-2/
hCD14 transfected HEK293 cells (HEK-Blue) by Lipid A 1 and 2 compared to
E. coli Re-LPS.
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the labile 1,1’-glycosylphosphodiester linkage intact. This con-
vergent approach could be effectively employed for the syn-
thesis of other relevant Lipid A structures entailing glycosyl
phosphate-linked aminosugar substitution. We have shown
that the long-chain pentaacyl Burkholderia Lipid A 2 was large-
ly inactive in eliciting the pro-inflammatory cytokines in
human cells, whereas Ara4N-modified Lipid A 1 induced con-
siderable pro-inflammatory innate immune signalling, though
at higher (micro-molar) concentrations compared with E. coli
LPS. Thus, biological assays revealed immuno-modulatory po-
tential of the Ara4N modification and showed boosted pro-in-
flammatory activity of Burkholderia Lipid A esterified by b-l-
Ara4N at the anomerically-linked phosphate. This finding is of
importance for understanding of the pro-virulent strategy of
the CF adapted BCC species and for the development of ad-
vanced CF-related therapeutics.
Experimental Section
General methods
Reagents and solvents were purchased from commercial suppliers
and used without further purification unless otherwise stated. Di-
chloromethane was distilled from CaH2 and stored over activated
4  molecular sieves. THF was distilled over Na/benzophenone di-
rectly before use. Other solvents were dried by storage over acti-
vated molecular sieves for at least 48 h prior to use (toluene (4 ),
acetonitrile (3 ) and DMF (3 )). Residual moisture was deter-
mined by colorimetric titration on a Mitsubishi CA-21 Karl Fischer
apparatus and did not exceed 20 ppm for dry solvents. Reactions
were monitored by TLC performed on silica gel 60 F254 HPTLC
pre-coated glass plates with a 25 mm concentration zone (Merck).
Spots were visualized by UV light followed by dipping into
a H2SO4/p-anisaldehyde solution or a ninhydrin/EtOH solution and
subsequent charring at 250 8C. Solvents were removed under re-
duced pressure at <40 8C. Preparative MPLC was performed on
silica gel 60 (230–400 mesh, Merck). Size exclusion chromatography
was performed on Sephadex LH20 (BioRad) or Sephadex SX1
(BioRad) supports. NMR spectra were recorded at 25 8C on a Bruker
Avance III 600 spectrometer (1H at 600.22 MHz; 13C at 150.92 MHz;
31P at 242.97 MHz) or on Bruker DPX 400 spectrometer (1H at
400.13 MHz; 13C at 100.61 MHz; 31P at 161.68 MHz) or on a Bruker
Avance 300 spectrometer (31P at 161.68 MHz) using standard
Bruker NMR software. Chemical shifts are reported in ppm;
13C NMR spectra are referenced to the residual solvent signal
(77.00 ppm for CDCl3, 49.00 ppm for MeOD).
31P NMR Spectra in
CDCl3 and CD3CN are referenced to external triphenylphosphine.
For the trisaccharides the NMR signals of the distal GlcN moiety
are indicated by primes, the signals of Ara4N moiety are indicated
by double primes. HPLC-LRMS was performed by injections of
0.01–0.1% CH3CN solutions into a Shimadzu LC-10AD VP system
equipped with two gradient pumps, degasser, a Shimadzu
LCMS 2020 detector and an AllTech 3300 ELSD detector. Analytes
were eluted over a Phenomenex Jupiter 5m C4 300A column using
linear gradients H2O (0.1% HCOOH)!CH3CN (0.1% HCOOH). High-
resolution mass spectrometry (HRMS) was carried out from acetoni-
trile solutions (1–10 mgL1) on LC-TOF MS (Agilent 1200SL HPLC
and Agilent 6210 ESI-TOF, Agilent Technologies). The data were an-
alysed by using Agilent Mass Hunter Software. MALDI-TOF was per-
formed using a Bruker Autoflex Speed TOF-TOF instrument with 6-
aza-2-thiothymine (ATT) as matrix. ESI-MS was performed on
a maXis Q-TOF mass spectrometer (Bruker, Bremen, Germany)
using ionization in positive ion mode on an ESI source with stan-
dard spray settings and 400–3500 m/z scan range, 100 ms transfer
time and 10 ms pre-pulse storage. The data were processed by
using standard Results Bruker Data Analysis 4.0 software. Optical
rotation was measured on a PerkinElmer 243 B polarimeter,
equipped with a Haake water circulation bath and a Haake D1 im-
mersion circulator for temperature control of the measuring cell.
a½ 20D Values are given in units of degdm1 cm3g1.
Ammonium 2,3-di-O-allyloxycarbonyl-4-azido-4-deoxy-b-l-arabi-
no-pyranosyl hydrogenphosphonate (6): A solution of 5 (170 mg,
0.50 mmol) in dry THF (10 mL) was added to a stirred solution of
salicylchlorophosphite (304 mg; 1.5 mmol) and pyridine (0.48 mL;
6 mmol) in dry THF (5 mL) at 0 8C under Ar. The reaction mixture
was stirred for 4 h at RT. Then, triethylamine (0.5 mL) and water
(0.5 mL) were added and the mixture was stirred for 15 min. The
reaction mixture was diluted with chloroform (100 mL) and
washed with 1m aqueous TEAB buffer (230 mL). The aqueous
phase was extracted with chloroform (250 mL) and the com-
bined organic phases were dried by filtration over cotton. The so-
lution was diluted with toluene (50 mL) and concentrated. The resi-
due was purified by chromatography on silica gel (chloroform/
methanol/25% aq. NH4OH, 16:4:0.5) to give 6 as a solid. Yield:
112 mg (55%). Rf=0.18 (CHCl3/MeOH/25% aq.NH4OH, 16:4:0.5);
a½ 20D = +108 (c=0.85 in chloroform); 1H NMR (600 MHz, CDCl3,
TMS): d=6.83 (d, JPH=649 Hz, 1H; H-P), 5.96–5.87 (m, 2H; 2=
CH, Alloc), 5.78 (dd, JP,1=8.8 Hz, J1,2=3.2 Hz, 1H; H-1), 5.38–5.32
(m, 2H; =CH2 Alloc trans), 5.30–5.25 (m, 3H; =CH2 Alloc cis, H-3),
5.04 (dd, J3,2=10.3 Hz, 1H; H-2), 4.70–4.60 (m, 4H; O-CH2-Alloc),
4.25 (m, 1H; H-4), 4.21 (ad, J5a,b=12.0 Hz, 1H; H-5a), 3.84 ppm (ad,
1H; H-5b); 13C NMR (151 MHz, CDCl3): d=154.05, 153.80 (C=O
Alloc), 131.21, 131.07 (=CH Alloc), 119.38, 119.19 (=CH2 Alloc),
91.67 (d, J=4.4 Hz, C-1), 72.51 (C-3), 71.67 (d, J=6.8 Hz, C-2), 69.27,
69.16 (OCH2 Alloc), 61.46 (C-5), 59.69 ppm (C-4);
31P NMR (243 MHz,
CDCl3): d=2.28 ppm; HRMS (ESI-TOF): m/z calcd for C13H17N3O10P:
406.0657 [MH] ; found: 406.0656.
tert-Butyldimethylsilyl 4-O-allyloxycarbonyl-6-O-[6-O-allyloxycar-
bonyl-3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-2-deoxy-4-
O-p-methoxybenzyl-2-(2,2,2-trichloroethoxycarbonylamino)-b-d-
glucopyranosyl]2-[(R)-3-(allyloxycarbonyloxy)hexadecanoylami-
no]-3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-2-deoxy-b-d-
glucopyranoside (21): A solution of 17 (535 mg, 0.53 mmol) and
20 (461 mg, 0.45 mmol) in dry dichloromethane (40 mL) was stirred
with powdered activated molecular sieves (4 , 50 mg) for 2 h
under Ar. The reaction mixture was cooled to 65 8C and a solution
of TMSOTf (0.055m, 1 mL, 0.055 mmol) in dry CH2Cl2 was added
dropwise. The reaction mixture was stirred for 1.5 h at 65 8C, the
temperature was allowed to rise to 30 8C and a solution of trie-
thylamine (50 mL) in dry CH2Cl2 (0.5 mL) was added. The mixture
was stirred for 10 min, warmed up to RT, diluted with dichlorome-
thane (100 mL) and filtered over a pad of Celite. The filtrate was di-
luted with CH2Cl2 (100 mL) and washed with sat. aq. NaHCO3 (2
50 mL) and water (50 mL). The organic phase was dried over
Na2SO4, filtered and concentrated. The residue was purified by
MPLC (toluene/ethyl acetate, 9:1!7:1) to give 21 (765 mg, 90%)
as a syrup. Rf=0.40 (toluene/ethyl acetate, 5:1) ; a½ 20D = +10 (c=
1.2 in chloroform); 1H NMR (600 MHz, CDCl3, TMS): d=7.19 (m, 2H;
m-CH Ar), 6.86 (m, 2H; o-CH Ar), 5.98–5.86 (m, 5H; 5 =CH Alloc),
5.84 (d, J2,NH=8.4 Hz, 1H; NH), 5.44 (d, J=8.8 Hz, 1H; N’H), 5.41–
5.21 (m, 12H; 5=CH2 Alloc, H-3, H-3’), 5.07 (m, 1H; b-CH
acyl), 4.99
(m, 1H; b-CHacyl), 4.96–4.92 (m, 2H; b-CHacyl, H-1), 4.80 (t, J3,4= J5,4=
9.5 Hz, 1H; H-4), 4.77 (d, Jgem=12.0 Hz, 1H; OCH2a Troc), 4.70 (d,
1H; OCH2b Troc), 4.66–4.53 (m, 11H; 5OCH2 Alloc, OCH2a PMB),
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4.49 (d, J2’,1’=8.3 Hz, 1H; H-1’), 4.45 (d, Jgem=10.9 Hz, 1H; OCH2b
PMB), 4.40 (dd, J6a’,b’=11.5 Hz, J5’,6a’=1.9 Hz, 1H; H-6a’), 4.22 (dd,
J5’,6b’=4.9 Hz, 1H; H-6b’), 3.95 (dd, J6a,b=11.5 Hz, J5,6a=2.1 Hz, 1H;
H-6a), 3.79 (s, 3H; OMe), 3.68–3.63 (m, 2H; H-2, H-5), 3.62 (at, J5’,4’=
J3’,4’=9.3 Hz, 1H; H-4’), 3.59–3.51 (m, 3H; H-6b, H-2’, H-5’), 2.62 (dd,
Jgem=16.4 Hz, Jvic=8.1 Hz, 1H; a-CHa
acyl), 2.56 (d, J=6.2 Hz, 2H; a-
CH2
acyl), 2.54 (dd, Jvic=4.6 Hz, 1H; a-CHb
acyl), 2.48 (dd, Jgem=15.2 Hz,
Jvic=6.4 Hz, 1H; a-CHa
acyl), 2.34 (dd, Jvic=5.6 Hz, 1H; a-CHb
acyl),
1.70–1.54 (m, 6H; g-CH2
acyl), 1.38–1.18 (m, 58H; CH2
acyl), 0.90–0.84
(m, 18H; w-CH3
acyl, tBu), 0.10, 0.08 ppm (2 s, 6H; 2Si-Me);
13C NMR (150 MHz, CDCl3): d=169.97, 169.87, 169.29 (2CO, CON-
Hacyl), 159.71 (Cq PMB), 154.82, 154.78, 154.64, 154.50, 154.28 (Cq
Alloc, Cq Troc), 131.86, 131.75, 131.73, 131.65, 131.51 (5=CH
Alloc), 130.06 (m-CH PMB), 129.50 (p-Cq PMB), 119.50, 119.25,
119.14, 119.06, 118.92 (5=CH2 Alloc), 114.16 (o-CH PMB), 101.05
(C-1’), 95.82 (C-1), 94.14 (CCl3 Troc), 75.48 (b-CH
acyl), 75.24 (C-4’),
75.09 (C-3’), 74.70 (CH2 Troc), 74.61, 74.57 (b-CH
acyl), 74.40 (CH2
PMB), 73.22 (C-5’), 72.98 (C-4), 72.82 (C-5), 72.47 (C-3), 69.24, 68.85,
68.60 (OCH2 Alloc), 68.08 (C-6), 66.12 (C-6’), 57.17 (C-2), 56.65 (C-2’),
55.41 (OMe), 41.48, 38.95, 38.63 (a-CH2
acyl), 34.28, 34.13, 33.99 (g-
CH2
acyl), 32.07, 29.85, 29.84, 29.81, 29.79, 29.74, 29.70, 29.69, 29.64,
29.57, 29.55, 29.51 (CH2
acyl), 25.79 (CH3 tBu), 25.28, 25.17, 25.10,
22.83 (CH2
acyl), 17.98 (Cq tBu), 14.25 (w-CH3
acyl), 3.82, 4.87 ppm
(Si-CH3); HRMS (
+ESI-TOF): m/z calcd for C93H149Cl3N2O28Si:
1875.9204 [M+H]+ ; found: 1875.9241.
tert-Butyldimethylsilyl 4-O-allyloxycarbonyl-6-O-(6-O-allyloxycar-
bonyl-3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-2-deoxy-4-
O-p-methoxybenzyl-2-[(R)-3-(tetradecanoyloxy)hexadecanoyl-
amino]-b-d-glucopyranosyl)-2-[(R)-3-(allyloxycarbonyloxy)hexa-
decanoylamino]-3-[(R)-3-(allyloxycarbonyloxy)-tetradecanoyl]-2-
deoxy-b-d-glucopyranoside (22): Zn dust (10 mm, 1.28 g,
19.55 mmol) was added to a stirred solution of 21 (367 mg,
0.20 mmol) in dioxane/acetic acid (2:1, 5 mL) and dispersed by ul-
trasonic treatment every 20 min. The reaction was stirred for
90 min and filtered over a pad of Celite. The filtrate was diluted
with ethyl acetate (150 mL) and washed with water (50 mL) and
sat. aq. NaHCO3 (350 mL) until the pH of organic phase reached
7.5. The organic phase was dried over Na2SO4, filtered and concen-
trated. The residue was dried by co-evaporation with dry toluene
(315 mL) and re-dissolved in dry chloroform (2 mL). A solution of
fatty acid 11 (188 mg, 0.39 mmol) in dry chloroform (2 mL) and
a solution EDC·HCl (75 mg, 0.39 mmol) in dry chloroform (1 mL)
were added to this stirred solution at 0 8C under Ar. The stirring
was continued for 48 h at 4 8C, the reaction mixture was diluted
with chloroform (150 mL) and washed with 10% aq. citric acid
(25 mL) and sat. aq. NaHCO3 (25 mL).The organic phase was dried
over Na2SO4, filtered and concentrated. The residue was purified by
MPLC (toluene/ethyl acetate, 1:0!8:1) to give 22 (283 mg, 67%)
as a syrup. Rf=0.39 (toluene/ethyl, acetate 5:1) ; a½ 20D = +12 (c=
1 in chloroform); 1H NMR (600 MHz, CDCl3, TMS): d=7.19 (m, 2H;
m-CH-Ar), 6.85 (m, 2H; o-CH-Ar), 6.04 (d, J=8.5 Hz, 1H; N’H), 5.98–
5.85 (m, 6H; 5=CH Alloc, NH), 5.40–5.22 (m, 11H; 5=CH2 Alloc,
H-3), 5.22 (dd, J4’,3’=8.6 Hz, J2’,3’=10.3 Hz, 1H; H-3’), 5.14–5.06 (m,
2H; 2b-CHacyl), 5.02–4.93 (m, 2H; 2b-CHacyl), 4.96 (d, J2,1=7.7 Hz,
1H; H-1), 4.78 (t, J3,4= J5,4=9.5 Hz, 1H; H-4), 4.67–4.49 (m, 11H; 5
OCH2 Alloc, OCH2a PMB), 4.51 (d, J2’,1’=8.3 Hz, 1H; H-1’), 4.42 (d,
Jgem=10.7 Hz, 1H; OCH2b PMB), 4.39 (dd, J6a’,b’=11.6 Hz, J5’,6a’=
2.0 Hz, 1H; H-6a’), 4.19 (dd, J5’,6b’=5.0 Hz, 1H; H-6b’), 3.91 (dd,
J6a,b=11.8 Hz, J5,6a=2.3 Hz, 1H; H-6a), 3.79 (s, 3H; OMe), 3.74 (ddd,
1H; H-2’), 3.67 (ddd, J6b,5=4.9 Hz, 1H; H-5), 3.62 (ddd, J3,2=10.5 Hz,
1H; H-2), 3.58 (t, J5’,4’=9.6 Hz, 1H; H-4’), 3.57 (dd, 1H; H-6b), 3.53
(ddd, 1H; H-5’), 2.62 (d, J=6.3 Hz, 2H; a-CH2
acyl), 2.56 (d, J=6.1 Hz,
2H; a-CH2
acyl), 2.49–2.42 (m, 2H; a-CH2
acyl), 2.40–2.27 (m, 4H; a-
CH2
acyl), 1.71–1.53 (m, 10H; 4g-CH2
acyl, b-CH2
acyl), 1.38–1.11 (m,
100H; CH2
acyl), 0.92–0.81 (m, 24H; w-CH3
acyl, tBu), 0.10, 0.07 ppm
(2s, 6H; 2SiMe); 13C NMR (150 MHz, CDCl3, TMS): d=173.88,
170.02, 169.95, 169.80, 169.27 (CO, CONH), 159.67 (Cq PMB), 154.84,
154.76, 154.59, 154.50, 154.39 (Cq Alloc), 131.88, 131.78, 131.75,
131.70, 131.51 (5=CH Alloc), 130.09 (m-CH PMB), 129.60 (p-Cq
PMB), 119.54, 119.16, 119.13, 119.03, 118.87 (5=CH2 Alloc), 114.13
(o-CH PMB), 101.11 (C-1’), 95.71 (C-1), 75.48 (b-CHacyl), 75.32 (C-3’),
75.27 (C-4’), 74.71, 74.59 (b-CHacyl), 74.29 (OCH2 PMB), 73.24 (C-4),
73.19 (C-5’), 72.72 (C-5), 72.66 (C-3), 70.85 (b-CHacyl), 69.26, 68.81,
68.58, 68.56, 65.53 (5OCH2 Alloc), 68.30 (C-6), 66.29 (C-6’), 57.23
(C-2), 55.39 (OMe), 54.85 (C-2’), 41.43, 38.92, 38.62, 34.66 (a-CH2
acyl),
34.42, 34.26, 34.17, 32.07 (g-CH2
acyl, b-CH2
acyl), 32.07, 29.91, 29.88,
29.87, 29.85, 29.83, 29.81, 29.77, 29.75, 29.73, 29.72, 29.70, 29.63,
29.62, 29.59, 29.53, 29.51, 29.43 (CH2
acyl), 25.79 (CH3 tBu), 25.48,
25.28, 25.24, 25.15, 25.12, 22.83 (CH2
acyl),17.98 (Cq tBu), 14.24 (w-
CH3
acyl), 3.84, 4.91 ppm (Si-CH3); MALDI-TOF: m/z calcd for
C120H204N2O29Si+C4H5N3OS (ATT): 2308.447 [M+ATT]
 ; found:
2308.392 (ATT=6-Aza-2-thiothymine).
tert-Butyldimethylsilyl 4-O-allyloxycarbonyl-6-O-(6-O-allyloxycar-
bonyl-3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-2-deoxy-2-
[(R)-3-(tetradecanoyloxy)hexadecanoylamino]-b-d-glucopyrano-
syl)-2-[(R)-3-O-(allyloxycarbonyloxy)hexadecanoylamino]-3-O-
[(R)-3-(allyloxy-carbonyloxy)tetradecanoyl]-2-deoxy-b-d-gluco-
pyranoside (23) and 4-O-allyloxycarbonyl-6-O-(6-O-allyloxycar-
bonyl-3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-2-deoxy-2-
[(R)-3-(tetradecanoyloxy)hexadecanoylamino]-b-d-glucopyrano-
syl)-2-[(R)-3-O-(allyloxycarbonyloxy)hexadecanoylamino]-3-O-
[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-2-deoxy-d-glucopyra-
nose (24): Trifluoroacetic acid (2.17 mL, 28.20 mmol) was added to
a stirred solution of 22 (679 mg, 0.31 mmol) in dry CH2Cl2 (20 mL).
The reaction was stirred for 15 min at RT, diluted with CH2Cl2
(200 mL) and washed with sat. aq. NaHCO3 (250 mL). The organic
phase was dried over Na2SO4, filtered and concentrated. The resi-
due was purified by MPLC (toluene/ethyl acetate, 5:1!3:2) to
afford 23 (480 mg, 75%) as a syrup and 24 (43 mg, 7%) as a syrup.
Compound 23 : Rf=0.45 (toluene/ethyl acetate 3:1) ; a½ 20D = +4 (c=
0.5 in chloroform); 1H NMR (600 MHz, CDCl3, TMS): d=6.01 (d, J=
8.2 Hz, 1H; N’H), 5.97–5.88 (m, 5H; 5=CH Alloc), 5.87 (d, J=
8.5 Hz, 1H; NH), 5.39–5.24 (m, 11H; 5=CH2 Alloc, H-3), 5.13–5.06
(m, 1H; b-CHacyl), 5.09 (dd, J4’,3’=8.3 Hz, J2’,3’=10.4 Hz, 1H; H-3’),
5.03–4.93 (m, 3H; 3b-CHacyl), 4.97 (d, J2,1=7.8 Hz, 1H; H-1), 4.80
(at, J3,4–J5,4=9.5 Hz, 1H; H-4), 4.66–4.57 (m, 10H; 5OCH2 Alloc),
4.57 (d, J2’,1’=8.2 Hz, 1H; H-1’), 4.48 (dd, J6a’,b’=11.7 Hz, J5’,6a’=
1.9 Hz, 1H; H-6a’), 4.35 (dd, J5’,6b’=5.0 Hz, 1H; H-6b’), 3.94 (dd,
J6a,b=11.6 Hz, J5,6a=2.3 Hz, 1H; H-6a), 3.71 (ddd, 1H; H-2’), 3.68
(ddd, J6b,5=4.9 Hz, 1H; H-5), 3.62 (ddd, J3,2=10.5 Hz, 1H; H-2), 3.58
(dd, 1H; H-6b), 3.59–3.51 (m, 2H; H-4’, H-5’), 3.16 (d, J=3.7 Hz, 1H;
OH), 2.66 (dd, Jvic=8.3 Hz, Jgem=15.3 Hz, 1H; a-CH2a
acyl), 2.58 (dd,
Jvic=3.4 Hz, 1H; a-CH2b
acyl), 2.57 (ad, Jvic=6.2 Hz, 2H; a-CH2
acyl),
2.49–2.25 (m, 6H; a-CH2
acyl, a-CH2
acyl), 1.74–1.51 (m, 10H; 4g-
CH2
acyl, b-CH2
acyl), 1.40–1.11 (m, 100H; CH2
acyl, CH2
acyl), 0.91–0.81 (m,
24H; w-CH3
acyl, w-CH3
acyl, tBu), 0.11, 0.08 ppm (2 s, 6H; 2Si-Me);
13C NMR (151 MHz, CDCl3): d=173.72, 171.20, 169.94, 169.78,
169.28 (CO, CONH), 155.21, 155.12, 154.76, 154.49, 154.40 (Cq
Alloc), 131.87, 131.72, 131.63, 131.49, 131.42 (5=CH Alloc), 119.63,
119.43, 119.25, 119.18, 118.89 (5 =CH2 Alloc), 101.10 (C-1’), 95.69
(C-1), 76.26 (C-3’), 75.76, 75.45, 74.60 (3b-CHacyl), 73.87 (C-5’),
73.22 (C-4), 72.64, 72.62 (C-3, C-5), 70.94 (b-CHacyl), 69.29 (OCH2
Alloc), 69.06 (C-4’), 68.89, 68.85, 68.60, 68.57 (4OCH2 Alloc), 68.23
(C-6), 66.63 (C-6’), 57.27 (C-2), 54.46 (C-2’), 41.51, 41.44, 39.99, 38.61
(4a-CH2
acyl), 34.81 (a-CH2
acyl), 34.64, 34.29, 34.27, 32.02 (g-CH2
acyl,
b-CH2
acyl), 32.08, 29.90, 29.88, 29.85, 29.82, 29.81, 29.80, 29.76,
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29.72, 29.66, 29.59, 29.53, 29.52, 29.42 (CH2
acyl), 25.80 (CH3 tBu),
25.52, 25.28, 25.24, 25.16, 25.14, 22.84 (CH2
acyl), 17.99 (Cq tBu), 14.26
(w-CH3
acyl), 3.83, 4.90 ppm (Si-CH3); HRMS (+ESI-TOF): m/z calcd
for C112H198N2O28Si: 1023.6945 [M+2H]
2+ ; found: 1023.6978.
Compound 24 : Rf=0.48 (toluene/ethyl acetate, 3:2) ; a½ 20D = +13
(c=0.3 in chloroform); 1H NMR (600 MHz, CDCl3, TMS, a/b=10:1,
a-anomer): d=6.03 (d, J=8.0 Hz, 1H; N’H), 5.97–5.85 (m, 6H; 5=
CH Alloc, NH), 5.40–5.23 (m, 11H; 5=CH2 Alloc, H-3), 5.18 (t, J2,1=
J1OH,1=3.3 Hz, 1H; H-1), 5.12 (dd, J4’,3’=8.6 Hz, J2’,3’=10.6 Hz, 1H;
H-3’), 5.06–4.97 (m, 4H; b-CHacyl), 4.96 (d, J2’,1’=8.2 Hz, 1H; H-1’),
4.81 (m, 1H; 1-OH), 4.67–4.55 (m, 11H; 5OCH2 Alloc, H-4), 4.49
(dd, J5’,6a’=2.0 Hz, J6a’,6b’=11.9 Hz, 1H; H-6a’), 4.40 (dd, J5’,6b’=4.3 Hz,
1H; H-6b’), 4.23–4.16 (m, 2H; H-2, H-5), 3.80 (dd, J6a,b=12.2 Hz,
J5,6a=1.5 Hz, 1H; H-6a), 3.69 (dd, J5,6b=7.5 Hz, 1H; H-6b), 3.64–3.51
(m, 3H; H-4’, H-5’, H-2’), 3.09 (d, JOH,4’=4.1 Hz, 1H; 4’-OH), 2.70–
2.16 (m, 10H; a-CH2
acyl), 1.75–1.51 (m, 10H; 4g-CH2
acyl, b-CH2
acyl),
1.47–1.11 (m, 100H; CH2
acyl), 0.88 ppm (t, J=7.0 Hz, 15H; w-CH3
acyl) ;
13C NMR (151 MHz, CDCl3): d=174.58, 171.04, 170.52, 170.49,
169.56 (CO, CONH), 155.36, 155.04, 154.64, 154.58, 154.34 (5Cq
Alloc), 131.87, 131.85, 131.52, 131.42, 131.39 (5=CH Alloc), 119.51,
119.41, 119.33, 119.01, 118.82 (5=CH2 Alloc), 100.62 (C-1’), 91.32
(C-1), 75.63, 75.57, 74.42 (b-CHacyl, C-3’), 73.99 (C-4’), 73.05 (C-4),
71.45, 71.42 (b-CHacyl, C-3), 69.60 (C-5), 69.20, 68.95, 68.91 (OCH2
Alloc), 68.84 (C-5’), 68.56, 68.52 (OCH2 Alloc), 67.91 (C-6), 66.41 (C-
6’), 55.13 (C-2’), 52.48 (C-2), 41.93, 41.33, 39.84, 38.77 (4a-CH2
acyl),
34.69 (a-CH2
acyl), 34.67, 34.48, 34.43, 34.17 (g-CH2
acyl, b-CH2
acyl),
32.08, 29.84, 29.82, 29.79, 29.75, 29.72, 29.68, 29.65, 29.60, 29.53,
29.51, 29.47, 29.38, 25.43, 25.20, 25.18, 25.16, 25.06, 22.84 (CH2
acyl),
14.26 ppm (w-CH3
acyl) ; HRMS (ESI) m/z calcd for C106H184N2O28
[M+2H]2+ : 966.6512; found: 966.6514.
4-O-Allyloxycarbonyl-6-O-(6-O-allyloxycarbonyl-4-O-(bisallyloxy)-
phosphoryl-3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-2-
deoxy-2-[(R)-3-(tetradecanoyloxy)hexadecanoylamino]-b-d-glu-
copyranosyl)-1-O-(bis-allyloxy)phosphoryl-2-[(R)-3-(allyloxycarbo-
nyloxy)-hexadecanoylamino]-3-O-[(R)-3-(allyloxycarbonyloxy)te-
tradecanoyl]-2-deoxy-a-d-glucopyranose (25): A solution of 1H-
tetrazole in dry acetonitrile (0.45m, 336 mL, 0.15 mmol) was added
to a stirred solution of 24 (39 mg, 0.02 mmol) and diallyl N,N-diiso-
propylphosphoramidite (40 mL, 0.15 mmol) in dry CH2Cl2 (3 mL)
under Ar. The reaction mixture was stirred for 1 h at RT and PNO
(46 mg, 0.15 mmol) was added under Ar at RT. The stirring was
continued for 15 min. The mixture was then diluted with CH2Cl2
(100 mL), washed with satd. aq. Na2S2O3/sat. aq. NaHCO3 (1:1,
30 mL), sat. aq. NaHCO3 (20 mL) and water (20 mL). The organic
phase was dried over Na2SO4, filtered and concentrated. The resi-
due was purified by column chromatography on silica gel (tolu-
ene/ethyl acetate, 3:1 supplemented with 0.5% NEt3), the residue
was additionally purified by precipitation as follows. The residue
was dissolved in CH2Cl2/acetone (1:1, 2 mL) and then petroleum
ether (8 mL) was added. Then the volume was reduced to 5 mL by
evaporation, the suspension was cooled to 0 8C and the solids
were separated on the glass filter. The filtrate was concentrated to
dryness and re-purified by precipitation. The combined precipitates
were purified by chromatography on silica gel (toluene/ethyl ace-
tate, 3:1 supplemented by 0.5% NEt3) to give 25 (38 mg, 84%) as
a syrup. Rf=0.30 (toluene/ethyl acetate, 2:1); a½ 20D = +29 (c=0.6
in chloroform); 1H NMR (600 MHz, CDCl3, TMS): d=6.73 (d, J=
8.3 Hz, 1H; N’H), 6.12 (d, J=8.2 Hz, 1H; NH), 5.99–5.85 (m, 9H; 5
=CH Alloc, 4=CH Allyl), 5.69 (dd, J2,1=3.3 Hz, JP,1=5.3 Hz, 1H; H-
1), 5.44–5.21 (m, 20H; 5=CH2 Alloc, 4=CH2 Allyl, H-3’, H-3),
5.21–5.15 (m, 1H; b-CHacyl), 5.10–5.05 (m, 1H; b-CHacyl), 5.02–4.96
(m, 2H; 2b-CHacyl), 4.93 (d, J2’,1’=8.3 Hz, 1H; H-1’), 4.83 (dd, J3,4=
9.6 Hz, J5,4=10.2 Hz, 1H; H-4), 4.66–4.44 (m, 19H; 5OCH2 Alloc,
4OCH2 Allyl, H-6a’), 4.34–4.25 (m, 3H; H-4’, H-6b’, H-2), 4.18 (ddd,
J5,6a=1.5 Hz, J5,6b=5.4 Hz, 1H; H-5), 3.86 (dd, J6a,b=12.3 Hz, 1H; H-
6a), 3.71 (dd, 1H; H-6b), 3.68–3.61 (m, 2H; H-5’, H-2’), 2.72 (dd,
Jvic=7.6 Hz, Jgem=16.9 Hz, 1H; a-CH2a
acyl), 2.68 (dd, Jvic=4.8 Hz, 1H;
a-CH2b
acyl), 2.60–2.53 (m, 2H; a-CH2
acyl), 2.51–2.37 (m, 4H; a-CH2
acyl),
2.35–2.23 (m, 2H; a-CH2
acyl), 1.70–1.50 (m, 10H; 4g-CH2
acyl, b-
CH2
acyl), 1.37–1.20 (m, 100H; CH2
acyl), 0.88 ppm (t, J=7.0 Hz, 15H;
w-CH3
acyl) ; 13C NMR (151 MHz, CDCl3): d=173.55, 170.71, 170.47,
169.84, 169.65 (CO, CONH), 154.79, 154.74, 154.68, 154.61, 154.06
(5Cq Alloc), 132.60, 132.56, 132.48, 132.44, 132.29, 132.25, 131.85,
131.83, 131.73, 131.25 (=CH Allyl, Alloc), 119.66, 119.35, 119.19,
119.08, 118.97, 118.95, 118.73, 118.63 (=CH2 Alloc, Allyl), 99.76 (C-1’),
95.57 (d, J=6.5 Hz, C-1), 75.19, 74.63, 74.42 (3b-CHacyl), 73.68 (d,
J=6.5 Hz, C-4’), 73.01 (C-3’), 72.64 (d, J=5.4 Hz, C-5’), 71.92 (C-5),
71.65 (C-4), 70.58 (b-CHacyl), 70.32 (C-3), 69.43, 69.17, 69.14, 68.90,
68.86, 68.83, 68.77, 68.65, 68.59, 68.46 (OCH2 Alloc, Allyl), 66.38 (C-
6), 65.99 (C-6’), 54.89 (C-2’), 52.24 (d, J=8.8 Hz, C-2), 40.99, 38.90,
38.65 (a-CH2
acyl), 34.56, 34.34, 34.27, 34.21 (a-CH2
acyl, g-CH2
acyl, b-
CH2
acyl), 32.09, 29.92, 29.89, 29.85, 29.82, 29.80, 29.75, 29.72, 29.68,
29.64, 29.61, 29.58, 29.53, 29.51, 29.44, 25.49, 25.25, 25.17, 25.12,
22.84 (CH2
acyl), 14.26 ppm (w-CH3
acyl) ; 31P NMR (243 MHz, CDCl3): d=
0.37, 1.56 ppm.
2-Deoxy-6-O-(2-deoxy-3-O-[(R)-3-hydroxytetradecanoyl]-4-O-
phosphoryl-2-[(R)-3-(tetradecanoyloxy)hexadecanoylamino]-b-d-
glucopyranosyl)-2-deoxy-2-[(R)-3-hydroxyhexadecanoylamino]-3-
O-[(R)-3-hydroxytetradecanoyl]-a-d-glucopyranose 1,4’-bisphos-
phate (triethylammonium salt) (2): To a stirred solution of 25
(14.5 mg, 6.43 mmol) in dry CHCl3/MeOH (4:1, 4 mL) was added
[CpRuIV(p-C3H5)(2-quinolinecarboxylato)]PF6 complex
[63] (4 mg,
6.6 mmol) and the reaction was stirred for 2 h at RT. The crude reac-
tion mixture was applied to a DEAE cellulose column (CH3COO

form, 110 cm) equilibrated with CHCl3/MeOH/H2O (2:3:1, v/v/v).
The column was washed with CHCl3/MeOH/H2O (2:3:1, 25 mL) and
then developed with a stepwise gradient (30 mL each) of 2:3:1
CHCl3/MeOH/aq. CH3COO
HNEt3
+ (0.06m!0.08m!0.12m!
0.2m). Appropriate fractions were collected, the total volume was
adjusted to 240 mL by addition of CHCl3/MeOH/H2O (2:3:1, v/v/v).
The solution was transferred to an extraction funnel and converted
to a two-phase Bligh–Dyer system by changing the solvent propor-
tions to 2:2:1.8 by addition of CHCl3 (40 mL) and water (68 mL).
The phases were resolved, the lower phase was concentrated, the
residue was desalted by dissolution in CHCl3/MeOH/H2O (2:3:1, v/
v/v, 180 mL) and rendering to a Bligh–Dyer mixture by addition of
CHCl3 (40 mL), methanol (10 mL) and water (60 mL). The phases
were resolved, and the lower phase was separated and concentrat-
ed. The residue was purified by gel permeation chromatography
on Sephadex SX1 (toluene/CH2Cl2/MeOH, 2:2:1) to afford 2 (5.3 mg,
50%) as a solid. Rf=0.6 (chloroform/pyridine/formic acid/metha-
nol/water, 50:50:14:2:5) or Rf=0.45 (CHCl3/MeOH/H2O, 100:75:15
supplemented with 0.5% of 33% aq. NH4OH,);
1H NMR (600 MHz,
CDCl3/MeOD, 4:1, TMS): d=5.52 (dd, 1H; J1,2=3.3 Hz, JP,1=6.6 Hz,
H-1), 5.18 (t, 1H; J2’,3’= J3’,4’=9.6 Hz, H-3’), 5.14 (t, 1H; J2,3= J3,4=
10.2 Hz, H-3), 5.09 (m, 1H; b-CHacyl), 4.68 (d, J2’,1’=8.2 Hz, 1H; H-1’),
4.28 (m, 1H; H-4’), 4.19 (m, 1H; H-2, under pre-saturated OH
signal), 4.06 (m, 1H; H-5), 4.04–3.94 (m, 3H; H-6a, 2b-CHacyl),
3.91–3.80 (m, 5H; b-CHacyl, H-2’, H-6’a, H-6’b, H-6b), 3.49–3.42 (m,
2H; H-4, H-5’), 3.13 (q, 4H; CH2, Et3NH
+-salt), 2.50–2.27 (m, 10H;
5a-CH2
acyl), 1.73–1.39 (m, 10H; 4g-CH2
acyl, b-CH2
acyl), 1.34 (t, 6H;
CH3, Et3NH
+-salt), 1.28–1.23 (m, 100H; -CH2
acyl), 0.86 ppm (t, J=
7.0 Hz, 15H; w-CH3
acyl) ; negative MALDI-TOF: m/z calcd for
C86H163NO24P2: 1670.108 [MH] ; found: 1670.051; positive ESI-MS:
m/z calcd for C86H164N2NaO24P2: 1694.12 [M+H]
+ ; found: 1694.10;
m/z calcd for C86H164N2Na2O24P2: 1716.06 [M+H]
+ ; found: 1716.08.
Chem. Eur. J. 2015, 21, 4102 – 4114 www.chemeurj.org  2015 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim4110
Full Paper
tert-Butyldimethylsilyl 4-O-allyloxycarbonyl-6-O-(6-O-allyloxycar-
bonyl-4-O-(bis-allyloxy)phosphoryl-3-O-[(R)-3-(allyloxycarbonyl-
oxy)-tetradecanoyl]-2-deoxy-2-[(R)-3-(tetradecanoyloxy)hexade-
canoyl-amino]-b-d-glucopyranosyl)-2-[(R)-3-(allyloxycarbonyloxy)-
hexadecanoylamino]-3-O-[(R)-3-(allyloxycarbonyloxy)tetradeca-
noyl]-2-deoxy-b-d-glucopyranoside (26): A solution of 1H-tetra-
zole in dry acetonitrile (0.45m, 500 mL, 0.22 mmol) was added to
a stirred solution of 23 (272 mg, 0.14 mmol) and diallyl N,N-diiso-
propylphosphoramidite (60 mL, 0.22 mmol) in dry CH2Cl2 (5 mL)
under Ar. The reaction mixture was stirred for 30 min at RT and
then PNO (70 mg, 0.22 mmol) was added. The stirring was contin-
ued for 10 min. , the mixture was diluted with CH2Cl2 (100 mL),
washed with 1n HCl (20 mL), sat. aq. Na2S2O3 (20 mL) and sat. aq.
NaHCO3 (10 mL). The organic phase was dried over Na2SO4, filtered
and concentrated. The residue was purified by column chromatog-
raphy on silica gel (toluene/ethyl acetate, 4:1) to give 26 (272 mg,
93%) as a syrup. Rf=0.31 (toluene/ethyl acetate, 4:1); a½ 20D = +13
(c=0.89 in chloroform); 1H NMR (600 MHz, CDCl3, TMS): d=6.08 (d,
J=7.5 Hz, 1H; N’H), 5.97–5.86 (m, 7H; 5=CH Alloc, 2=CH Allyl),
5.85 (d, J=8.8 Hz, 1H; NH), 5.53 (dd, J4’,3’=8.8 Hz, J2’,3’=10.4 Hz,
1H; H-3’), 5.39–5.21 (m, 15H; 5 =CH2 Alloc, 2 =CH2 Allyl, H-3),
5.18–5.12 (m, 1H; b-CHacyl), 5.08–5.03 (m, 1H; b-CHacyl),), 5.01–4.93
(m, 2H; b-CHacyl), 4.99 (d, J2’,1’=8.2 Hz, 1H; H-1’), 4.92 (d, J2,1=
7.7 Hz, 1H; H-1), 4.76 (t, J3,4= J5,4=9.5 Hz, 1H; H-4), 4.68–4.57 (m,
10H; 5OCH2 Alloc), 4.53 (dd, J6a’,b’=11.6 Hz, J5’,6a’=2.0 Hz, 1H; H-
6a’), 4.53–4.45 (m, 4H; 2-OCH2 Allyl), 4.31 (t, J=9.2 Hz, 1H; H-4’),
4.26 (dd, J5’,6b’=5.6 Hz, 1H; H-6b’), 3.88 (dd, J6a,b=11.5 Hz, J5,6a=
2.8 Hz, 1H; H-6a), 3.75–3.68 (m, 3H; H-2, H-5, H-5’), 3.64 (dd, J5,6b=
5.4 Hz, 1H; H-6b), 3.32 (ddd, 1H; H-2’), 2.73 (dd, J=4.5 Hz, J=
16.1 Hz, 1H; a-CH2a
acyl), 2.65 (dd, J=7.4 Hz, 1H; a-CH2b
acyl), 2.60–
2.25 (m, 8H; a-CH2
acyl), 1.73–1.50 (m, 10H; 4g-CH2
acyl, b-CH2
acyl),
1.39–1.10 (m, 100H; CH2
acyl), 0.88 (t, 15H; 5w-CH3
acyl), 0.87 (s, 9H;
tBu), 0.10, 0.08 ppm (2 s, 6H; 2Si-Me); 13C NMR (150 MHz, CDCl3):
d=173.81, 170.34, 169.87, 169.55, 169.22 (CO, CONH), 154.75,
154.54, 154.51, 154.20 (Cq Alloc), 132.47, 132.38 (2  =CH Allyl),
131.87, 131.75, 131.74, 131.61, 131.54 (5 =CH Alloc), 119.50,
119.45, 119.12, 119.10, 118.89, 118.74 (=CH2 Alloc, =CH2 Allyl),
100.05 (C-1’), 95.84 (C-1), 75.46, 74.92, 74.57 (3b-CHacyl), 73.81 (d,
J=6.9 Hz, C-4’), 73.45 (C-4), 72.78 (C-3), 72.51 (C-5), 72.41 (d, J=
5.7 Hz, C-5’), 72.26 (C-3’), 70.53 (b-CHacyl), 69.22, 68.89, 68.85, 68.81,
68.65, 68.56 (OCH2 Alloc, Allyl, C-6), 65.99 (C-6’), 57.03 (C-2), 56.22
(C-2’), 41.44, 41.21, 38.89, 38.63, 34.60 (5a-CH2
acyl), 34.49, 34.27,
34.12, 34.03 (g-CH2
acyl, b-CH2
acyl), 32.08, 29.91, 29.88, 29.87, 29.84,
29.83, 29.78, 29.76, 29.73, 29.61, 29.58, 29.52, 29.44 (CH2
acyl), 25.79
(CH3 tBu), 25.42, 25.28, 25.19, 25.12, 22.84 (CH2
acyl), 17.98 (Cq tBu),
14.25 (w-CH3
acyl), 3.84, 4.94 ppm (Si-CH3); 31P NMR (243 MHz,
CDCl3): d=1.65 ppm; HRMS (+ESI-TOF): m/z calcd for
C118H207N2O31PSi : 1103.7089 [M+2H]
2+ ; found: 1103.7073.
4-O-Allyloxycarbonyl-6-O-(6-O-allyloxycarbonyl-4-O-(bis-allyl-
oxy)-phosphoryl-3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-
2-deoxy-2-[(R)-3-(tetradecanoyloxy)hexadecanoylamino]-b-d-glu-
copyranosyl)-2-[(R)-3-(allyloxycarbonyloxy)hexadecanoylamino]-
3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-2-deoxy-d-gluco-
pyranose (27): Triethylamine hydrofluoride (TREAT, 263 mL,
1.61 mmol) was added to a solution of 26 (145 mg, 0.07 mmol) in
dry THF (3 mL) in a PTFE flask, and the reaction was stirred under
Ar at RT for 48 h. Then the mixture was diluted with ethyl acetate
(200 mL) and washed sat. NaHCO3 (50 mL), 1m HCl (20 mL) and
sat. aq. NaHCO3 (50 mL). The organic phase was dried over Na2SO4,
filtered and concentrated. The residue was purified by MPLC (tolu-
ene/ethyl acetate 3:1!1:1) to afford 27 (120 mg, 87%) as a syrup.
Rf=0.45 (toluene/ethyl acetate 1:1) ; a½ 20D = +21 (c=0.66 in chloro-
form); 1H NMR (600 MHz, CDCl3, TMS): a/b=10:1, for a-anomer:
d)=6.20 (d, J=7.3 Hz, 1H; N’H), 5.98–5.84 (m, 8H; 5=CH Alloc,
2=CH Allyl, NH), 5.48 (dd, J4’,3’=8.6 Hz, J2’,3’=10.7 Hz, 1H; H-3’),
5.45 (d, J2’,1’=8.2 Hz, 1H; H-1’), 5.39–5.21 (m, 15H; 5=CH2 Alloc,
2=CH2 Allyl, H-3), 5.19 (at, J2,1 ~ JOH,1=3.1 Hz, 1H; H-1), 5.14–4.96
(m, 4H; b-CHacyl), 4.96–4.94 (m, 1H; -OH), 4.66–4.55 (m, 11H; 5-
OCH2 Alloc, H-4), 4.55–4.44 (m, 5H; 2-OCH2 Allyl, H-6a’), 4.36 (t,
J=9.2 Hz, 1H; H-4’), 4.31 (dd, J5’,6b’=4.7 Hz, J6a’,6b’=12.1 Hz, 1H; H-
6b’), 4.23–4.18 (m, 1H; H-2), 4.18–4.14 (m, 1H; H-5), 3.78 (dd, J6a,b=
12.8 Hz, J5,6a=7.6 Hz, 1H; H-6a), 3.74–3.68 (m, 2H; H-6b, H-5’), 3.23
(ddd, 1H; H-2’), 2.76 (dd, J=4.6 Hz, J=15.8 Hz, 1H; a-CH2a
acyl), 2.62
(dd, J=7.1 Hz, 1H; a-CH2b
acyl), 2.59 (dd, J=7.7 Hz, J=16.3 Hz, 1H;
a-CH2a
acyl), 2.53 (dd, J=5.1 Hz, 1H; a-CH2b
acyl), 2.50–2.26 (m, 6H; a-
CH2
acyl), 1.74–1.52 (m, 10H; 4g-CH2
acyl, b-CH2
acyl), 1.44–1.11 (m,
100H; CH2
acyl), 0.88 (t, J=7.0 Hz, 15H; w-CH3
acyl) ; 13C NMR
(150 MHz, CDCl3): d=174.37, 171.02, 170.48, 169.59, 169.53 (CO,
CONH), 154.87, 154.63, 154.60, 154.50, 154.28 (5Cq Alloc), 132.43,
132.38, 132.33, 131.90, 131.88, 131.60, 131.53, 131.41 (=CH Allyl,
Alloc), 119.68, 119.38, 119.19, 118.94, 118.80, 118.74 (=CH2 Alloc,
Allyl), 99.28 (C-1’), 91.36 (C-1), 75.56, 75.07, 74.42 (3b-CHacyl),
73.60 (d, J=5.5 Hz, C-4’), 73.02 (C-4), 72.66 (d, J=6.1 Hz, C-5’),
72.12 (C-3’), 71.57 (C-3), 70.81 (b-CHacyl), 70.23 (C-5), 69.18, 68.88,
68.85, 68.79, 68.54, 68.51 (OCH2 Alloc, Allyl), 67.39 (C-6), 65.70 (C-
6’), 56.49 (C-2’), 52.36 (C-2), 41.68, 41.29, 39.03, 38.75, 34.59 (5a-
CH2
acyl), 34.51, 34.46, 34.16, 34.07 (g-CH2
acyl, b-CH2
acyl), 32.08, 29.88,
29.86, 29.85, 29.83, 29.77, 29.71, 29.69, 29.61, 29.60, 29.58, 29.52,
25.40, 25.42, 25.33, 25.22, 25.14, 25.06, 22.84 (CH2
acyl), 14.26 ppm
(w-CH3
acyl) ; 31P NMR (243 MHz, CDCl3): d=1.75 ppm; HRMS (+ESI-
TOF): m/z calcd for C112H195N3O31P: 2109.3507 [M+NH4]
+ ; found:
2109.3538.
2,3-Di-O-allyloxycarbonyl-4-azido-4-deoxy-b-l-arabinopyranosyl-
1-O-phosphoryl 4-O-allyloxycarbonyl-6-O-(6-O-allyloxycarbonyl-
4-O-(bis-allyloxy)phosphoryl-3-O-[(R)-3-(allyloxycarbonyloxy)te-
tradecanoyl]-2-deoxy-2-[(R)-3-(tetradecanoyloxy)hexadecanoyl-
amino]-b-d-glucopyranosyl)-2-[(R)-3-(allyloxycarbonyloxy)hexa-
decanoylamino]-3-O-[(R)-3-(allyloxycarbonyloxy)tetradecanoyl]-
2-deoxy-a-d-glucopyranose triethylammonium salt (28): A solu-
tion of PyNTP (196 mg, 0.393 mmol) in CH2Cl2 (0.5 mL) and a solu-
tion of 2,6-lutidine (130 mL, 1.12 mmol) in CH2Cl2 (0.5 mL) were
added successively to a stirred solution of 27 (a/b 10:1; 25 mg,
0.012 mmol) and H-phosphonate 6 (47.6 mg, 0.112 mmol) in dry
CH3CN/CH2Cl2 (4:1, 3 mL) and the reaction was stirred for 5 h at RT
under Ar. N,O-Bis(trimethylsilyl)acetamide (137 mL, 0.56 mmol) fol-
lowed by triethylamine (78 mL, 0.73 mmol) were added under Ar
and the stirring was continued for 15 min. Then, (1S)-(+)-(10-cam-
phorsulfonyl)oxaziridine (CSO) (232 mg, 1.01 mmol) was added and
the reaction mixture was stirred for 15 min at RT under Ar. The
mixture was diluted with chloroform (30 mL) and washed with
a mixture of a 7% Na2S2O3 solution/1m TEAB buffer (1:1, 10 mL).
The aqueous phase was re-extracted with chloroform (250 mL),
the combined organic phases were dried by filtration over cotton,
diluted with toluene (10 mL) and concentrated. The residue was
purified by chromatography on silica gel (ethyl acetate/acetone,
3:1 supplemented with 0.5% triethylamine) to give 28 (19 mg,
61%) as a transparent solid. Rf=0.36 (ethyl acetate/acetone 2:1);
a½ 20D = +43 (c=0.73 in chloroform); 1H NMR (600 MHz, CDCl3/
MeOD, 4:1, TMS): d=5.89–5.79 (m, 9H; 7=CH Alloc, 2=CH
Allyl), 5.82 (dd, J2,1=3.5 Hz, JP,1=7.4 Hz, 1H; H-1’’ Ara4N), 5.53 (dd,
J2,1=3.3 Hz, JP,1=7.1 Hz, 1H; H-1), 5.39–5.32 (m, 9H; 2=CH2 Alloc,
2=CH2 Allyl, H-3’), 5.30–5.24 (m, 12H; 5=CH2 Alloc, H-3, H-
3’’Ara4N), 5.20 (m, 1H; b-CHacyl), 5.15 (m, 1H; H-2’’Ara4N), 5.10 (m,
1H; b-CHacyl), 5.03–4.98 (m, 2H; 2b-CHacyl), 4.80–4.88 (d, 1H; J2’,1’=
10.3 Hz, H-1’), 4.86 (t, J3,4= J4,5=8.3 Hz, 1H; H-4), 4.71–4.48 (m,
19H; 7OCH2 Alloc, 2OCH2 Allyl, H-6’a), 4.25 (t, J=9.2 Hz, 1H; H-
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4’), 4.23–4.15 (m, 4H; H-6’b, H-4’’Ara4N, H-5a’’ Ara4N, H-2), 4.15–
4.10 (m, 1H; H-5 under water signal), 3.94 (dd, J5a,b=12.9 Hz, J4,5a=
1.8 Hz, 1H; H-5a’’ Ara4N), 3.90 (dd, J6a,b=12.1 Hz, J5,6a=2.0 Hz, 1H;
H-6a), 3.67 (ddd, J4’,5’=9.8 Hz, J6a’,5’=1.5 Hz, J6b’,5’=5.0 Hz, 1H; H-5’),
3.65 (dd, J1’,2’=8.5 Hz, J3’,2’=10.5 Hz, 1H; H-2’), 3.56 (dd, J5,6b=
4.2 Hz, 1H; H-6b), 5.74 (q, J=9.2 Hz, 6H; CH2 NEt3), 2.66 (dd, J=
7.6 Hz, J=17.3 Hz, 1H; a-CH2a
acyl), 2.62 (dd, J=4.8 Hz, 1H; a-
CH2b
acyl), 2.52–2.09 (m, 8H; a-CH2
acyl), 1.62–1.44 (m, 10H; 4g-
CH2
acyl, b-CH2
acyl), 1.36–1.04 (m, 109H; CH2
acyl, CH3 NEt3), 0.80 ppm
(t, J=7.0 Hz, 15H; w-CH3
acyl) ; 13C NMR (150 MHz, CDCl3/MeOD 4:1):
d=173.74, 170.97, 170.16, 169.96, 169.82 (CO, CONH), 154.55,
154.45, 154.40, 154.00, 153.83, 153.74 (Cq Alloc), 131.64, 131.53,
131.48, 131.29, 131.19, 130.93 (=CH Allyl, Alloc), 118.91, 118.86,
118.82, 118.70, 118.63, 118.44, 118.39, 118.26 (=CH2 Alloc, Allyl),
99.44 (C-1’), 94.19 (d, J=5.8 Hz, C-1 GlcN), 93.02 (d, J=6.8 Hz, C-
1’’), 75.18, 74.28, 74.13 (3b-CHacyl), 73.63 (d, J=6.4 Hz, C-4’), 72.66
(C-3’), 72.44 (C-3’’), 72.00 (d, J=5.3 Hz, C-5’), 71.81 (C-4), 71.22,
71.17, 71.12 (C-3, C-2’’Ara4N), 70.43 (b-CHacyl), 69.97 (C-5), 68.98,
68.91, 68.86, 68.83, 68.75, 68.71, 68.53, 68.13 (OCH2 Alloc, Allyl),
66.28 (C-6), 65.59 (C-6’), 61.02 (C-5’’), 59.39 (C-4’’), 54.41 (C-2’),
51.32 (d, J=7.5 Hz, C-2), 45.95 (CH2 NEt3), 40.62, 39.95, 38.19, 38.07
(a-CH2
acyl), 34.25, 34.13, 33.91, 33.86, 33.81, (a-CH2
acyl, g-CH2
acyl, b-
CH2
acyl), 31.73, 29.59, 29.54, 29.51, 29.48, 29.46, 29.43, 29.38, 29.36,
29.35, 29.30, 29.17, 29.08, 25.20, 24.94, 24.88, 24.81, 24.69, 22.46
(CH2
acyl), 13.73 (w-CH3
acyl), 8.28 ppm (CH3 NEt3);
31P NMR (243 MHz,
CDCl3): d=1.97, 0.48 ppm; HRMS (+ESI-TOF): m/z calcd for
C125H207N5O41P2: 1249.1944 [M+2H]
2+ ; found: 1249.1943.
4-Amino-b-l-arabinopyranosyl-1-O-phosphoryl 2-deoxy-6-O-(2-
deoxy-3-O-[(R)-3-hydroxytetradecanoyl]-4-O-phosphoryl-2-[(R)-3-
(tetradecanoyloxy)hexadecanoylamino]-b-d-glucopyranosyl)-2-
deoxy-2-[(R)-3-hydroxyhexadecanoylamino]-3-O-[(R)-3-hydroxy-
tetradecanoyl]-a-d-glucopyranose (1): The complex [CpRuIV(p-
C3H5)(2-quinolinecarboxylato)]PF6 (2 mg, 3.3 mmol) was added to
a stirred solution of 28 (6 mg, 2.3 mmol) in dry CHCl3/MeOH (4:1,
2 mL) and the reaction was stirred for 2 h at RT. The reaction mix-
ture was directly applied onto a DEAE cellulose column (HCOO
form, 15 cm). The column was washed with CHCl3/MeOH (4:1,
20 mL) and then developed with CHCl3/MeOH/0.2m methanolic
CH3COO
HNEt3
+ , 2:3:1). Appropriate fractions were collected and
the total volume was adjusted to 240 mL by addition of 2:3:1
CHCl3/MeOH/H2O. The solution was transferred to an extraction
funnel and converted to a two-phase Bligh–Dyer system by chang-
ing the solvent proportions to 2:2:1.8 by addition of CHCl3 (40 mL)
and water (68 mL). The phases were resolved, the lower phase was
filtered over cotton, diluted with toluene (10 mL) and concentrated
to give an intermediate azide 4-azido-4-deoxy-b-l-arabinopyrano-
syl-1-O-phosphoryl 2-deoxy-6-O-(2-deoxy-3-O-[(R)-3-hydroxytetrade-
canoyl]-4-O-phosphoryl-2-[(R)-3-(tetradecanoyloxy)hexadecanoyl-
amino]-b-d-glucopyranosyl)-2-deoxy-2-[(R)-3-hydroxyhexadecanoy-
lamino]-3-O-[(R)-3-hydroxytetradeca-noyl]-a-d-glucopyranose
(5 mg, 99%) as a syrup; Rf=0.60 (chloroform/methanol/water
100:75:15); (negative MALDI-TOF: m/z calcd for C91H170N5O27P2:
1827.156 [MH] ; found: 1827.230). PtO2 (2 mg, 9 mmol) was
added to a stirred solution of the intermediate azide (5.0 mg,
2.6 mmol) in dry toluene/MeOH (4:1, 1.2 mL). The atmosphere was
exchanged to hydrogen and the reaction was stirred for 2 h at RT
under H2. The solids were removed by filtration over a syringe filter
(0.45 mm, regenerated cellulose) and washed with toluene/MeOH
(4:1, 10 mL). The filtrate was concentrated, the residue was purified
by gel permeation chromatography on Sephadex LH-20 (150 cm;
elution with toluene/MeOH, 1:1). Yield: 3.4 mg (70%) as a light-
pink coloured solid (a mixture of several salt forms at phosphate:
triethylammonium (white) and ruthenium (pink) salts). Alternative-
ly, the residue (originating from the same amount of the azide:
5 mg) was purified by anion-exchange chromatography on a DEAE
cellulose column (HCOO-form, 101 cm) as follows. The column
was equilibrated with 2:3:1 (v/v/v) CHCl3/MeOH/H2O. The residue
was dissolved in CHCl3/MeOH (3:1, 2 mL) and let slowly absorbed
onto a resin pad. The column was washed with CHCl3/MeOH/H2O
(2:3:1, 25 mL) and then developed with the stepwise gradient
(30 mL each) of 2:3:1 CHCl3/MeOH/aq. CH3COO
HNEt3
+ (0.04m!
0.06m!0.8m!0.12m). Appropriate fractions were collected, the
total volume was adjusted to 240 mL by addition of CHCl3/MeOH/
H2O (2:3:1, v/v/v). The solution was transferred to an extraction
funnel and converted to a two-phase Bligh–Dyer system by chang-
ing the solvent proportions to 2:2:1.8 by addition of CHCl3 (40 mL)
and water (68 mL). The phases were resolved, the lower phase was
concentrated, the residue was desalted by a dissolution in CHCl3/
MeOH/H2O (2:3:1, v/v/v, 180 mL) and rendering into a Bligh–Dyer
mixture by addition of CHCl3 (40 mL), methanol (10 mL) and water
(60 mL). The phases were resolved in the extraction funnel, and
the lower phase was separated and concentrated. The residue was
purified by chromatography on Sephadex SX1 (160 cm, toluene/
CH2Cl2/MeOH, 2:2:1) to afford 1 (triethylammonium salt, 2.8 mg,
57%) as a white solid. Rf=0.35 (chloroform/pyridine/formic acid/
methanol/water, 50:50:14:2:5) or Rf=0.65 (CHCl3/MeOH/H2O,
100:75:15, supplemented with 0.5% of 33% aq. NH4OH,) ;
1H NMR
(600 MHz, CDCl3-MeOD, 4:1): d=5.56 (m, 1H; H-1’’), 5.51 (m, 1H;
H-1), 5.10–5.25 (m, 3H; H-3’, H-3), b-CHacyl), 4.77 (d, J2’,1’=8.0 Hz,
1H; H-1’), 4.34 (m, 1H; H-4’), 4.25 (m, 1H; H-2, under pre-saturated
OH signal), 4.15–3.80 (m, 9H; H-5’’a, H-5, H-2’’, H6a, H-2’, H-6’a, 3
b-CHacyl), 3.75–3.50 (m, 4H; H-5’’b, H-4’’, H-6b), 3.60–3.50 (m, 2H;
H-4, H-5’), 3.15 (q, CH2, Et3NH
+-salt), 2.50–1.90 (m, 5a-CH2
acyl),
1.68–1.50 (m, 4g-CH2
acyl, b-CH2
acyl, CH3, Et3NH
+-salt), 1.10–1.40 (m,
CH2
acyl), 0.83 ppm (t, 5w-CH3
acyl) ; positive ESI-MS: m/z calcd for
C91H174N3O27P2: 1803.18 [M+H]
+ ; found: 1803.15; m/z calcd for
C91H173N3NaO27P2: 1825.16 [M+H]
+ ; found: 1825.14; m/z calcd for
C91H172N3Na2O27P2: 1874.14 [M+H]
+ ; found: 1874.12.
Biological assays
Reagents and cell cultures : HEK293 stably expressing human
TLR4, MD-2, CD14 and a secreted NF-kB dependent reporter (HEK-
Blue hTLR4), E. coli O111:B4 LPS, E. coli serotype R515 Re-LPS were
purchased from InvivoGen. The THP-1 cell line was obtained from
Dr. Rene Devos (Roche Research Ghent) and originally purchased
from ATCC. 12-O-Tetradecanoylphorbol-13-acetate (TPA) was pur-
chased from Sigma. Lipid A 1 and 2 were reconstituted in DMSO/
chloroform (2:1, v/v) to provide 1 mgmL1 stock solutions. Further
dilutions were made with cell medium (RPMI or DMEM) supple-
mented with 10% FCS so that the final amount of DMSO/chloro-
form in the cell culture did not exceed 0.01%.
hTLR4/MD-2/CD14-Transfected HEK293 cells (Hek-Blue) activa-
tion assay : Growth conditions and activation assay were set as rec-
ommended by InvivoGen. The cells were stimulated with the solu-
tions of compounds 1 and 2 or Re-LPS in DMEM supplemented by
10% FCS at the indicated concentrations. The compounds were
added in a total volume of 20 mL to 25000 HEK-Blue hTLR4 cells in
180 mL plates and were incubated for 20–24 h at 37 8C and 5%
CO2. SEAP levels were determined by incubation of 20 mL of chal-
lenged cells supernatants with 180 mL detection reagent (QUANTI-
Blue) and the colour development was measured at 650 nm using
a spectrophotometer (SpectraMAX 190). Data were combined from
n=3 independent experiments, error bars indicate standard error
of the mean.
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Assay in human macrophage-like cell line THP1: THP-1 cells were
grown in RPMI-1640 cell-culture medium (Life Technologies) that
was supplemented with 2 mmL glutamine, 100 UmL1 penicillin,
100 mgmL1 streptomycin, and 10% FCS. Cells were seeded in
a 96 well plate at 10E5 cells/well in 150 mL complete medium and
stimulated by 200 nm TPA for 24 h to induce the differentiation
into macrophage-like cells. On the next day the cells were washed
twice with complete culture medium to discard the cells that did
not adhere, refreshed with 200 mL complete medium and left for
1 h to recover. Cells were stimulated with compounds 1 and 2 at
the indicated concentration and with E. coli O111:B4 LPS, which
were added as solutions in 10 mL complete medium. The total
volume of the well after stimulation reached 220 mL. The cells were
incubated for 18 h and the supernatants were analysed for TNF-a,
IL-8 and MCP-1 by ELISA (BD Biosciences). Data are representative
for two independent experiments. Error bars indicate standard
error of the mean of duplicate samples.
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